Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Woerner, M. G. Articles by Kane, J. M. Search for Related Content PubMed Citation Articles by Woerner, M. G. Articles by Kane, J. M. Miscellaneous Mood Disorders Stroke Dementias (General) Other Neuroleptics

Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors

Objective:The purposes of this study were to investigate the rate (incidence) of tardive dyskinesia in elderly patients beginning treatment with antipsychotic medication and to identify risk factors for development of tardive dyskinesia in this age group. Method:A group of 261 neuroleptic-naive patients aged 55 or above were identified at the time they were starting antipsychotic drug treatment. This group is the complete study group; a preliminary report based on the first 160 patients was published previously. Patients were evaluated at baseline and followed up at 3-month intervals for periods ranging from 3 to 393 weeks. Assessments included abnormal involuntary movements, extrapyramidal signs, psychiatric symptoms, and medical and drug treatment histories.Results:The cumulative rates of tardive dyskinesia were 25%, 34%, and 53% after 1, 2, and 3 years of cumulative antipsychotic treatment. A greater risk of tardive dyskinesia was associated with history of ECT treatment, higher mean daily and cumulative antipsychotic doses, and presence of extrapyramidal signs early in treatment. Differences in tardive dyskinesia rates between diagnostic groups found in univariate analyses were attenuated when the authors controlled for these variables.Conclusions:Tardive dyskinesia rates for patients beginning treatment with conventional antipsychotics in their fifth decade or later are three to five times what has been found for younger patients, despite treatment with lower doses. Alternative treatments need to be investigated. Am J Psychiatry 1998; 155: 1521-1528

This article has been cited by other articles:

				C. Kenney, C. Hunter, A. Davidson, and J. Jankovic Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia J. Clin. Pharmacol., March 1, 2008; 48(3): 379 - 384. [Full Text] [PDF]

				K. L. Claxton, J. J. Chen, and D. M. Swope Drug-Induced Movement Disorders Journal of Pharmacy Practice, December 1, 2007; 20(6): 415 - 429. [Abstract] [PDF]

				R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease Arch Gen Psychiatry, November 1, 2007; 64(11): 1259 - 1268. [Abstract] [Full Text] [PDF]

				P. Damier, S. Thobois, T. Witjas, E. Cuny, P. Derost, S. Raoul, P. Mertens, J.-C. Peragut, J.-J. Lemaire, P. Burbaud, et al. Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia Arch Gen Psychiatry, February 1, 2007; 64(2): 170 - 176. [Abstract] [Full Text] [PDF]

				J. M. Kane Tardive Dyskinesia Circa 2006 Am J Psychiatry, August 1, 2006; 163(8): 1316 - 1318. [Full Text] [PDF]

				D. E. Tenback, P. N. van Harten, C. J. Slooff, J. van Os, and SOHO Study Group Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study Am J Psychiatry, August 1, 2006; 163(8): 1438 - 1440. [Abstract] [Full Text] [PDF]

				D. Stueber and C. M. Swartz Carvedilol suppresses intractable hiccups. J Am Board Fam Med, July 1, 2006; 19(4): 418 - 421. [Abstract] [Full Text] [PDF]

				G. REMINGTON Rational pharmacotherapy in early psychosis The British Journal of Psychiatry, August 1, 2005; 187(48): s77 - s84. [Abstract] [Full Text] [PDF]

				C. U. CORRELL, J. M. KANE, and S. LEUCHT Dr. Correll and Colleagues Reply Am J Psychiatry, February 1, 2005; 162(2): 405 - 406. [Full Text] [PDF]

				C. U. Correll, S. Leucht, and J. M. Kane Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies Am J Psychiatry, March 1, 2004; 161(3): 414 - 425. [Abstract] [Full Text] [PDF]

				Drugs for disruptive features in dementia DTB, January 1, 2003; 41(1): 1 - 4. [Abstract] [Full Text] [PDF]

				M. A. Boyd Atypical Antipsychotics: Impact on Overall Health and Quality of Life Journal of the American Psychiatric Nurses Association, August 1, 2002; 8(4_suppl): S9 - S17. [Abstract] [PDF]

				Tardive Dyskinesia in the Elderly Journal Watch (General), November 20, 1998; 1998(1120): 2 - 2. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us